Author Topic: (AAN) Risk of disease progression after starting Tecfidera...  (Read 233 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9549
  • MS diagnosed 1980
  • Location: Pacific Northwest
Presented at the recent annual AAN conference in Washington, DC:

[P3.269] Risk of Disease Progression after Starting Dimethyl Fumurate (DMF): Data from the Providence Multiple Sclerosis Centerís DMF Registry

Kyle Smoot, Kiren Kresa-Reahl, Chiayi Chen, Tamela Stuchiner, Bobbie Lee Roth, Stanley Cohan

Portland, OR, USA.


To determine the risk of clinical relapses and MRI progression in patients treated with DMF [dimethyl fumarate = Tecfidera].


Given the results of two Phase III trials and the greater convenience of an oral medication, we anticipated a strong interest in DMF. Because data concerning transition from prior disease modifying therapy to DMF is limited, a registry was established to monitor the utilization of DMF and the treatment outcomes.


Subjects prescribed DMF from March 2013 to September 2014 were identified. Charts are reviewed at the time of starting DMF and then every 6 months.


321 identified patients have been followed for a mean of 9.3 months; 103 (32.1%) were previously treated with interferon beta (INFβ), 52 (16.2%) with glatiramer acetate (GA), 13 (4.0%) with fingolimod, 54 (16.8%) with natalizumab, 17 (5.3%) with other agents. 30 patients (9.3%) were newly diagnosed , and 52 (16.2%) had been off prior treatment for at least 6 months before starting DMF.

Clinical relapses occurred in 44 (13.7%) patients. Of those, 18 (40.9%) of the relapses occurred within the first 3 months, 10 ( 22.7%) between month 3 and 6, and 16 (36.4%) between month 6 and 12 after starting DMF.

MRI results are available from 171 (53.3%) patients, 143 (83.6%) of which were stable.

To date, 81 (25.2%) patients have stopped DMF including 27 (8.4%) secondary to clinical or radiographic progression and 58 (18.0%) secondary to side effects.


The majority of relapses on DMF occurred within the first 3 months after starting therapy. The risk of relapse was high in patients who were newly diagnosed (26.7%) and transitioning from natalizumab (18.5%). Mean washout period was 8 weeks for those who relapsed.

Patients who previously were on fingolimod had a high rate of relapse; however, the number was relatively small, 4 (30.8%).

Category - MS and CNS Inflammatory Disease: Health Services/Outcomes Research

Session: P3: Poster Session III: MS and CNS Inflammatory Diseases: Treatment Efficacy, Safety and Tolerability (2:00 PM-6:30 PM)
Date/Time: Tuesday, April 21, 2015 - 2:00 pm

The abstract can be seen here.
« Last Edit: May 07, 2015, 02:38:12 pm by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.